INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,771,813 | +54.8% | 160,200 | +88.0% | 0.28% | +8.5% |
| Q1 2023 | $1,144,236 | +8.6% | 85,200 | 0.0% | 0.26% | +2.4% |
| Q4 2022 | $1,053,924 | -11.4% | 85,200 | 0.0% | 0.25% | +7.2% |
| Q3 2022 | $1,189,000 | -81.1% | 85,200 | -81.3% | 0.24% | -79.3% |
| Q2 2022 | $6,281,000 | +998.1% | 455,000 | +1194.5% | 1.14% | +1426.7% |
| Q1 2022 | $572,000 | -1.4% | 35,149 | -1.4% | 0.08% | -13.8% |
| Q4 2021 | $580,000 | +13.1% | 35,665 | +3.2% | 0.09% | +141.7% |
| Q3 2021 | $513,000 | -26.7% | 34,565 | -1.2% | 0.04% | -36.8% |
| Q2 2021 | $700,000 | -77.5% | 35,000 | -74.1% | 0.06% | -45.7% |
| Q1 2021 | $3,116,000 | -64.9% | 135,000 | -27.2% | 0.10% | -85.1% |
| Q2 2020 | $8,888,000 | -36.4% | 185,500 | -16.5% | 0.71% | -32.8% |
| Q1 2020 | $13,983,000 | -86.2% | 222,100 | -72.9% | 1.05% | -93.6% |
| Q4 2019 | $101,589,000 | – | 819,800 | – | 16.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |